Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Chiron's Proleukin recommended for approval for new indication

Dec. 23, 1997

New antitumor agent in development in China

Dec. 22, 1997

Idec's immunotherapy shows promise in phase I/II for non-Hodgkin's lymphoma

Dec. 22, 1997

MAb for non-Hodgkin's lymphoma now available in U.S.

Dec. 19, 1997

Novopharm Biotech's hMAb enters phase I in Canada

Dec. 19, 1997

Seragen reports preliminary results of pivotal CTCL study

Dec. 17, 1997

Phase II results reported for Bexxar

Dec. 15, 1997

Cel-Sci expands Multikine trial

Dec. 12, 1997

New data on PDL's SMART M195 antibody reported

Dec. 12, 1997

FDA approves Neoprobe's IND for RIGS/ACT therapy

Dec. 11, 1997

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...